Market Overview:
The global rhabdomyosarcoma drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing incidence of rhabdomyosarcoma, rising demand for targeted therapies, and growing investments in research and development (R&D) activities. Based on type, the global rhabdomyosarcoma drug market is segmented into ARI-4175, Celyvir, Crizotinib, Enoblituzumab, AT-69, Axitinib and others. Based on application, the market is segmented into research center, hospital clinic and others. Geographically speaking North America dominates the global rhabdomyosarcoma drug market followed by Europe owing to better reimbursement scenario in these regions coupled with rising incidence rates of cancer patients in these regions.
Product Definition:
Rhabdomyosarcoma is a rare form of cancer that starts in the muscles. It can occur almost anywhere in the body, but most often occurs in the head and neck, bladder, vagina, or testicles. Rhabdomyosarcoma is treated with chemotherapy and radiation therapy.
ARI-4175:
ARI-4175 is a potent and novel oral inhibitor of mTOR, with IC 50 of 0.1 mg/L. It has shown to have inhibitory activity against mTOR both in vitro and in vivo, with an EC 50 value of 0.098 mg/L for human recombinant tissue extract (HRET).
Celyvir:
Celyvirs (Sotradecol) is used for the treatment of Rhabdomyosarcoma. It is an immunomodulating drug that works by changing the way the body's immune system reacts to cancer cells. This medicine has been found to be effective in combination with chemotherapy and radiation therapy, which makes it a promising drug for use in treating patients with this form of cancer.
Application Insights:
The research center application segment led the global market in 2017. This is attributed to increasing R&D activities pertaining to cancer treatment and development of new drugs for various types of rhabdomyosarcoma. Increasing number of government-supported cancer research centers in developing countries such as China, India, Brazil and Mexico is also expected to contribute significantly towards revenue generation over the forecast period.
Rising awareness among patients regarding availability of advanced treatment options for various cancers including R&D investments by pharmaceutical companies coupled with growing spending capacity due to high GDP growth rates has resulted in increased usage of these drugs at clinical stages subsequent stage trials which are conducted only on a trial basis before FDA approval for marketing purposes. This factor has propelled market growth during preclinical studies phase II & III where these medicines are tested against other treatments or chemotherapy with fewer side effects compared to conventional therapies thus driving demand globally over the forecast period (2017 To 2030).
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the presence of key players, increased R&D activities, and high healthcare expenditure in this region. Moreover, increasing cases of sarcomas have led to an increase in demand for these drugs over the past few years. For instance, according to data published by American Cancer Society (ACS), Inc., around 1,845 new cases were reported in U.S.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure especially after 2020 when Japan’s fiscal year ends.
Growth Factors:
- Increasing incidence of rhabdomyosarcoma
- Growing demand for targeted therapies for rhabdomyosarcoma
- Rising awareness about rhabdomyosarcoma among patients and healthcare professionals
- Technological advancements in the diagnosis and treatment of rhabdomyosarcoma
- Availability of novel drugs for the treatment of rhabdomyosarcoma
Scope Of The Report
Report Attributes
Report Details
Report Title
Rhabdomyosarcoma Drug Market Research Report
By Type
ARI-4175, Celyvir, Crizotinib, Enoblituzumab, AT-69, Axitinib, Others
By Application
Research Center, Hospital, Clinic, Others
By Companies
Bellicum Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Celgene Corp, Eisai Co Ltd, Epizyme Inc, Exelixis Inc, Iproteos SL, Ipsen SA, MacroGenics Inc, Bellicum Pharmaceuticals Inc, Novartis AG, Noxxon Pharma AG, Pfizer Inc, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Tarveda Therapeutics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Rhabdomyosarcoma Drug Market Report Segments:
The global Rhabdomyosarcoma Drug market is segmented on the basis of:
Types
ARI-4175, Celyvir, Crizotinib, Enoblituzumab, AT-69, Axitinib, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research Center, Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bellicum Pharmaceuticals Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Celgene Corp
- Eisai Co Ltd
- Epizyme Inc
- Exelixis Inc
- Iproteos SL
- Ipsen SA
- MacroGenics Inc
- Bellicum Pharmaceuticals Inc
- Novartis AG
- Noxxon Pharma AG
- Pfizer Inc
- Taiho Pharmaceutical Co Ltd
- Taiwan Liposome Company Ltd
- Tarveda Therapeutics Inc
Highlights of The Rhabdomyosarcoma Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ARI-4175
- Celyvir
- Crizotinib
- Enoblituzumab
- AT-69
- Axitinib
- Others
- By Application:
- Research Center
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rhabdomyosarcoma Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rhabdomyosarcoma drug is a medication that is used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major companies in the rhabdomyosarcoma drug market are Bellicum Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Celgene Corp, Eisai Co Ltd, Epizyme Inc, Exelixis Inc, Iproteos SL, Ipsen SA, MacroGenics Inc, Bellicum Pharmaceuticals Inc, Novartis AG, Noxxon Pharma AG, Pfizer Inc, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Tarveda Therapeutics Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rhabdomyosarcoma Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Rhabdomyosarcoma Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Rhabdomyosarcoma Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Rhabdomyosarcoma Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Rhabdomyosarcoma Drug Market Size & Forecast, 2020-2028
4.5.1 Rhabdomyosarcoma Drug Market Size and Y-o-Y Growth
4.5.2 Rhabdomyosarcoma Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ARI-4175
5.2.2 Celyvir
5.2.3 Crizotinib
5.2.4 Enoblituzumab
5.2.5 AT-69
5.2.6 Axitinib
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Research Center
6.2.2 Hospital
6.2.3 Clinic
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rhabdomyosarcoma Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rhabdomyosarcoma Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ARI-4175
9.6.2 Celyvir
9.6.3 Crizotinib
9.6.4 Enoblituzumab
9.6.5 AT-69
9.6.6 Axitinib
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Research Center
9.10.2 Hospital
9.10.3 Clinic
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ARI-4175
10.6.2 Celyvir
10.6.3 Crizotinib
10.6.4 Enoblituzumab
10.6.5 AT-69
10.6.6 Axitinib
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Research Center
10.10.2 Hospital
10.10.3 Clinic
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ARI-4175
11.6.2 Celyvir
11.6.3 Crizotinib
11.6.4 Enoblituzumab
11.6.5 AT-69
11.6.6 Axitinib
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Research Center
11.10.2 Hospital
11.10.3 Clinic
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ARI-4175
12.6.2 Celyvir
12.6.3 Crizotinib
12.6.4 Enoblituzumab
12.6.5 AT-69
12.6.6 Axitinib
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Research Center
12.10.2 Hospital
12.10.3 Clinic
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ARI-4175
13.6.2 Celyvir
13.6.3 Crizotinib
13.6.4 Enoblituzumab
13.6.5 AT-69
13.6.6 Axitinib
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Research Center
13.10.2 Hospital
13.10.3 Clinic
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rhabdomyosarcoma Drug Market: Competitive Dashboard
14.2 Global Rhabdomyosarcoma Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bellicum Pharmaceuticals Inc
14.3.2 Boehringer Ingelheim GmbH
14.3.3 Bristol-Myers Squibb Co
14.3.4 Celgene Corp
14.3.5 Eisai Co Ltd
14.3.6 Epizyme Inc
14.3.7 Exelixis Inc
14.3.8 Iproteos SL
14.3.9 Ipsen SA
14.3.10 MacroGenics Inc
14.3.11 Bellicum Pharmaceuticals Inc
14.3.12 Novartis AG
14.3.13 Noxxon Pharma AG
14.3.14 Pfizer Inc
14.3.15 Taiho Pharmaceutical Co Ltd
14.3.16 Taiwan Liposome Company Ltd
14.3.17 Tarveda Therapeutics Inc
